Skip Navigation



Rheumatology Advance Access published online on July 20, 2004
Rheumatology, doi:10.1093/rheumatology/keh325
Rheumatology © British Society for Rheumatology 2004; all rights reserved
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary data
Right arrow All Versions of this Article:
43/11/1383    most recent
keh325v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lampropoulos, C. E.
Right arrow Articles by D'Cruz, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lampropoulos, C. E.
Right arrow Articles by D'Cruz, D. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received March 1, 2004
Accepted June 21, 2004

Concise report

Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative

C. E. Lampropoulos 1, S. Sangle 1, P. Harrison 1, G. R. V. Hughes 1, D. P. D'Cruz 1*

1 Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, UK

* To whom correspondence should be addressed. E-mail: david.d'cruz{at}kcl.ac.uk.


  Abstract

Objective. To determine the efficacy of tacrolimus ointment 0.1% on resistant cutaneous lesions in patients with lupus erythematosus.

Methods. Twelve patients with skin manifestations were studied. Six had discoid lupus (DL), four subacute cutaneous lupus erythematosus (SCLE) and two systemic lupus erythematosus (SLE). All patients had extensive skin lesions refractory to previous treatment. Patients received topical tacrolimus 0.1% for a minimum of 6 weeks and response was evaluated by physicians' and patients' assessment and documented with photographs at baseline and at the end of the treatment.

Results. Eleven of 12 patients completed the therapy. One patient with DL discontinued because of side-effects--peeling and a burning sensation. Six patients were clearly improved, one patient had a minor remission of his face lesion while in four the rashes remained the same. Two patients with SCLE had significant regression of their lesions while the other two had no improvement. In DL, two had certain improvement, one minor improvement and two were without response. The patients with SLE had significant amelioration of their extensive photosensitive rash.

Conclusion. Tacrolimus ointment 0.1% may be an effective alternative in patients with severe resistant cutaneous manifestations in lupus erythematosus.

Keywords: Tacrolimus; Cutaneous lupus erythematosus.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
A. Tlacuilo-Parra, E. Guevara-Gutierrez, F. Gutierrez-Murillo, A. Soto-Ortiz, F. Barba-Gomez, M. Hernandez-Torres, and M. Salazar-Paramo
Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus
Rheumatology, December 1, 2005; 44(12): 1564 - 1568.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.